US Patent No. 9,872,922

ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES


Patent No. 9,872,922
Issue Date January 23, 2018
Title Anti-efna4 Antibody-drug Conjugates
Inventorship Marc Isaac Damelin, Park Ridge, NJ (US)
Kiran Manohar Khandke, Nanuet, NY (US)
Puja Sapra, River Edge, NJ (US)
Alexander John Bankovich, San Francisco, CA (US)
Scott J. Dylla, Emerald Hills, CA (US)
Assignee Pfizer Inc., New York, NY (US) AbbVie Stemcentrx LLC, North Chicago, IL (...

Claim of US Patent No. 9,872,922

1. A method of treating an EFNA-associated neoplastic disorder comprising administering a therapeutically effective amount
of a composition comprising an antibody-drug conjugate of the formula Ab-(L-D) to a subject in need thereof, wherein:
(a) Ab is an antibody, or antigen-binding fragment thereof, that binds to EFNA4 and comprises a heavy chain variable region
comprising three CDRs set forth as SEQ ID NOs: 15, 19, and 23 and a light chain variable region comprising three CDRs set
forth as SEQ ID NOs: 29, 33, and 35; and

(b) L-D is a linker-drug moiety, wherein L is a linker and D is a drug, and wherein D is a calicheamicin or calicheamicin
derivative.